Log in

Relevant bibliographies by topics / Radiochemical / Journal articles

To see the other types of publications on this topic, follow the link: Radiochemical.

Journal articles on the topic 'Radiochemical'

Author: Grafiati

Published: 5 June 2025

Last updated: 15 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Radiochemical.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Yang, Chang-Tong, Pei Ing Ngam, Vanessa Jing Xin Phua, et al. "Radiochemical Feasibility of Mixing of 99mTc-MAA and 90Y-Microspheres with Omnipaque Contrast." Molecules 27, no. 21 (2022): 7646. http://dx.doi.org/10.3390/molecules27217646.

Full text

Abstract:

Yttrium-90 (90Y) microspheres are widely used for the treatment of liver-dominant malignant tumors. They are infused via catheter into the hepatic artery branches supplying the tumor under fluoroscopic guidance based on pre-therapy angiography and Technetium-99m macroaggregated albumin (99mTc-MAA) planning. However, at present, these microspheres are suspended in radiolucent media such as dextrose 5% (D5) solution. In order to monitor the real-time implantation of the microspheres into the tumor, the 90Y microspheres could be suspended in omnipaque contrast for allowing visualization of the correct distribution of the microspheres into the tumor. The radiochemical purity of mixing 90Y-microspheres in various concentrations of omnipaque was investigated. The radiochemical purity and feasibility of mixing 99mTc-MAA with various concentrations of a standard contrast agent were also investigated. Results showed the radiochemical feasibility of mixing 90Y-microspheres with omnipaque is radiochemically acceptable for allowing real-time visualization of radioembolization under fluoroscopy.

APA, Harvard, Vancouver, ISO, and other styles

2

Sholter, Dalton, and Paul Davis. "Radiochemical Synovectomy." Scandinavian Journal of Rheumatology 26, no. 5 (1997): 337–41. http://dx.doi.org/10.3109/03009749709065694.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Murray, Royce W. "Radiochemical analysis." Analytical Chemistry 71, no. 9 (1999): 293A. http://dx.doi.org/10.1021/ac990327m.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Dei Cas, Michele, Linda Montavoci, Sara Casati, Nadia Malagolini, Fabio Dall’Olio, and Marco Trinchera. "Convenient and Sensitive Measurement of Lactosylceramide Synthase Activity Using Deuterated Glucosylceramide and Mass Spectrometry." International Journal of Molecular Sciences 24, no. 6 (2023): 5291. http://dx.doi.org/10.3390/ijms24065291.

Full text

Abstract:

Lactosylceramide is necessary for the biosynthesis of almost all classes of glycosphingolipids and plays a relevant role in pathways involved in neuroinflammation. It is synthesized by the action of galactosyltransferases B4GALT5 and B4GALT6, which transfer galactose from UDP-galactose to glucosylceramide. Lactosylceramide synthase activity was classically determined in vitro by a method based on the incorporation of radiolabeled galactose followed by the chromatographic separation and quantitation of the product by liquid scintillation counting. Here, we used deuterated glucosylceramide as the acceptor substrate and quantitated the deuterated lactosylceramide product by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). We compared this method with the classical radiochemical method and found that the reactions have similar requirements and provide comparable results in the presence of high synthase activity. Conversely, when the biological source lacked lactosylceramide synthase activity, as in the case of a crude homogenate of human dermal fibroblasts, the radiochemical method failed, while the other provided a reliable measurement. In addition to being very accurate and sensitive, the proposed use of deuterated glucosylceramide and LC-MS/MS for the detection of lactosylceramide synthase in vitro has the relevant advantage of avoiding the costs and discomforts of managing radiochemicals.

APA, Harvard, Vancouver, ISO, and other styles

5

Jáchymov, Mariánské Lázně. "13th Radiochemical conference." Journal of Radioanalytical and Nuclear Chemistry Articles 210, no. 1 (1996): i. http://dx.doi.org/10.1007/bf02055424.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Erickson, Mitchell D., Joseph H. Aldstadt, Jorge S. Alvarado, Jeffrey S. Crain, Kent A. Orlandini, and Lesa L. Smith. "Radiochemical method development." Journal of Hazardous Materials 41, no. 2-3 (1995): 351–58. http://dx.doi.org/10.1016/0304-3894(94)00108-s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Larenkov, Anton, Iurii Mitrofanov, and Marat Rakhimov. "Improvement of End-of-Synthesis Radiochemical Purity of 177Lu-DOTA-PSMA-Ligands with Alternative Synthesis Approaches: Conversion Upswing and Side-Products Minimization." Pharmaceutics 16, no. 12 (2024): 1535. https://doi.org/10.3390/pharmaceutics16121535.

Full text

Abstract:

Background: Radiochemical purity is a key criterion for the quality of radiopharmaceuticals used in clinical practice. The joint improvement of analytical methods capable of identifying related radiochemical impurities and determining the actual radiochemical purity, as well as the improvement of synthesis methods to minimize the formation of possible radiochemical impurities, is integral to the implementation of high-tech nuclear medicine procedures. PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treatment option for prostate cancer, and [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMAI&T have achieved global recognition as viable radiopharmaceuticals. Recently, it was shown that specific radiochemical impurities can form during the synthesis of [177Lu]Lu-PSMA-617 because of a spontaneous, thermally mediated condensation of the Glu-C(O)-Lys fragment, resulting in the formation of three different cyclic forms (with no affinity for PSMA). During this study, we identified another impurity, a product of detachment of the Glu-CO fragment from PSMA-617, caused by heating. The total content of all four thermally mediated degradation products may reach 9–11% during classical incubation for 30 min at 95 °C, reducing the radiochemical purity to an unacceptable level (albeit with high levels of radiochemical conversion). It is reasonable to assume that the formation of similar impurities is characteristic of all PSMA-specific vectors that contain Glu-C(O)-Lys pharmacophores. Because the formation of these impurities directly depends on the temperature and incubation time, to reduce their content in the reaction mixture at the end of the synthesis, it is necessary to select conditions to achieve a high level of radiochemical conversion for the minimum possible time and/or at the minimum sufficient temperature. Methods: In this study, using [177Lu]Lu-PSMA-617 as an example, we evaluated the efficiency of alternative methods of synthesis with microwave heating and co-solvent (ethanol) addition to ensure radiochemical yield and radiochemical purity in the shortest possible time and at the minimum necessary and sufficient synthesis temperature. Results: Both approaches achieved a significant reduction in the impurities content, while achieving satisfactory synthesis yields in a short time. In addition to improving the synthesis parameters and radiochemical purity, the use of microwave heating and the addition of ethanol reduces the negative influence of other auxiliaries on labeling kinetics. Notably, the addition of ethanol under certain conditions allowed [177Lu]Lu-PSMA-617 to be synthesized at room temperature for only 10 min. This makes it possible to achieve exceptionally high real radiochemical purity of the preparations, determined only by the quality of the original precursor. The approaches considered in this study can be successfully applied to improve the synthesis process and quality parameters of the finished product, both for known radiopharmaceuticals and for those under development.

APA, Harvard, Vancouver, ISO, and other styles

8

Maiyesni, M., M. Mujinah, D. Kurniasih, et al. "A Modified Method for Increasing Radiochemical Purity of I-125 for Radiopharmaceuticals." Atom Indonesia 1, no. 1 (2023): 1–5. http://dx.doi.org/10.55981/aij.2023.1243.

Full text

Abstract:

Iodine-125 (125I) is one of the radioisotopes widely used in radiopharmaceuticals for diagnosis and therapy of various cancers. Recent reports indicate that there has been shortages in the world supply of this radioiodine isotope. One of the absolute requirements good radiopharmaceuticals must meet is radiochemical purity, which generally has to be above 95 %, with an efficiency of over 90 %. The previous investigation shows that the radiochemical purity is low and does not meet the radiochemical requirement. In this work, we aim at improving the previous method by modifying the Jones reductor-based method. The modified method includes reduction and uniformization of Zn particle sizes, Zn particle compaction, and the performance of reduction process in a closed process flow. The Jones reductor converted impurities into products; in this case, iodate (IO3-) and periodate (IO4-) impurities were converted into iodide (I-), so that 125I product fulfills the radiochemical purity requirements and yielded high efficiency. In this investigation, the 125I previous product was, for the first time, improved with a radiochemical purity of 99.24 % and an efficiency of 97.98 %.

APA, Harvard, Vancouver, ISO, and other styles

9

Lien, V. T., and P. J. Riss. "Radiosynthesis of [18F]Trifluoroalkyl Groups: Scope and Limitations." BioMed Research International 2014 (2014): 1–10. http://dx.doi.org/10.1155/2014/380124.

Full text

Abstract:

The present paper is concerned with radiochemical methodology to furnish the trifluoromethyl motif labelled with18F. Literature spanning the last four decades is comprehensively reviewed and radiochemical yields and specific activities are discussed.

APA, Harvard, Vancouver, ISO, and other styles

10

Guisande, N., J. Sanchez, L. Garavaglia, et al. "EFFECT OF THE RADIOCHEMICAL IMPURITIES OF99mTC-MIBI ON THEDIAGNOSTIC QUALITY OF THE IMAGES IN NUCLEAR MEDICINE." Anales AFA 32, no. 3 (2021): 72–75. http://dx.doi.org/10.31527/analesafa.2021.32.3.72.

Full text

Abstract:

This work analyzes the reliability of the radiochemical purity control method of99mTc-MIBI used in nuclear medicine services and the influence of the greater presence of radiochemical impurities in the diagnostic quality of the obtained images.

APA, Harvard, Vancouver, ISO, and other styles

11

Maskur, Maskur, Enny Lestari, Amal Rezka Putra, et al. "Determination of Radiochemical Purity of 99mTc-DTPA Using One-System Method of Paper Chromatography." Journal of Pure and Applied Chemistry Research 8, no. 2 (2019): 109–16. http://dx.doi.org/10.21776/ub.jpacr.2019.008.02.461.

Full text

Abstract:

The more efficient and effective quality control techniques for 99mTc-DTPA are needed because 99mTc has a short half-life of around 6.0 hours. We have succeeded in developing a one-system of Thin Layer Chromatography (TLC) for radiochemical purity testing system that is faster and more practical. Two-system method of TLC for radiochemical purity testing uses mobile phase of methyl ethyl ketone indicated as system A and 0.9% sodium chloride solution indicated as system B. One-system method uses the mobile phase of a mixture solution of acetone and 0.9% sodium chloride. In this study, the determination of radiochemical purity of the one-system of TLC has been successfully developed using the Whatman-1 paper stationary phase and the mixture of mobile phase between acetone and 0.9% sodium chloride solution. The mobile phase of acetone: 0.9% sodium chloride with a ratio of 9:1 shows the most optimum results. This phase can separate 99mTc-DTPA (Rf = 0.4-0.6) from 99mTcO4- (Rf = 0.9-1.0) and 99mTcO2 (Rf = 0.0-0.1) as radiochemical impurities. This result shows that the one-system of TLC method can be used for radiochemical purity testing of 99mTc-DTPA radiopharmaceutical kits. This method can completely separate the product compound (99mTc-DTPA) from its impurities (99mTcO2 and 99mTcO4-).

APA, Harvard, Vancouver, ISO, and other styles

12

KIRSTEN, T. "Radiochemical Solar Neutrino Experiments." Annals of the New York Academy of Sciences 647, no. 1 Texas/ESO-Cer (1991): 392–93. http://dx.doi.org/10.1111/j.1749-6632.1991.tb32186.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Ehmann, William D., J. David Robertson, and Steven W. Yates. "Nuclear and radiochemical analysis." Analytical Chemistry 62, no. 12 (1990): 50–70. http://dx.doi.org/10.1021/ac00211a005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Gavrin, V. N., and B. T. Cleveland. "Radiochemical solar neutrino experiments." Nuclear Physics B - Proceedings Supplements 221 (December 2011): 90–97. http://dx.doi.org/10.1016/j.nuclphysbps.2011.03.100.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Ehmann, William D., and Steven W. Yates. "Nuclear and radiochemical analysis." Analytical Chemistry 60, no. 12 (1988): 42–62. http://dx.doi.org/10.1021/ac00163a003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Espartero, A. G., J. A. Suárez, M. Rodrı́guez, and G. Piña. "Radiochemical analysis of 93Zr." Applied Radiation and Isotopes 56, no. 1-2 (2002): 41–46. http://dx.doi.org/10.1016/s0969-8043(01)00164-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Ehmann, William D., J. David Robertson, and Steven W. Yates. "Nuclear and radiochemical analysis." Analytical Chemistry 64, no. 12 (1992): 1–22. http://dx.doi.org/10.1021/ac00036a001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Ehmann, William D., J. David Robertson, and Steven W. Yates. "Nuclear and Radiochemical Analysis." Analytical Chemistry 66, no. 12 (1994): 229–51. http://dx.doi.org/10.1021/ac00084a011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Ehmann, William D., and Steven W. Yates. "Nuclear and radiochemical analysis." Analytical Chemistry 58, no. 5 (1986): 49–65. http://dx.doi.org/10.1021/ac00296a005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Zaharescu, T., and C. Podinǎ. "Radiochemical stability of EPDM." Polymer Testing 20, no. 2 (2001): 141–49. http://dx.doi.org/10.1016/s0142-9418(00)00015-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Abbas, Hafiz G., M. Yunus, and Ludwig E. Feinendegen. "Radiochemical synthesis of etomoxir." Applied Radiation and Isotopes 69, no. 2 (2011): 415–17. http://dx.doi.org/10.1016/j.apradiso.2010.10.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Bujdosó, E. "Radiochemistry and radiochemical separations." Journal of Radioanalytical and Nuclear Chemistry 242, no. 1 (1999): 241–50. http://dx.doi.org/10.1007/bf02345929.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Bujdosó, E. "Radiochemistry and radiochemical separations." Journal of Radioanalytical and Nuclear Chemistry 240, no. 1 (1999): 397–408. http://dx.doi.org/10.1007/bf02349189.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Bujdosó, E. "Radiochemistry and radiochemical separations." Journal of Radioanalytical and Nuclear Chemistry 222, no. 1-2 (1997): 283–88. http://dx.doi.org/10.1007/bf02034288.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Bujdosó, E. "Radiochemistry and radiochemical separations." Journal of Radioanalytical and Nuclear Chemistry Articles 132, no. 2 (1989): 443–60. http://dx.doi.org/10.1007/bf02136102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Ashok Rao, K., and B. Rangamannar. "Radiochemical determination of antimony." Journal of Radioanalytical and Nuclear Chemistry Letters 93, no. 5 (1985): 295–302. http://dx.doi.org/10.1007/bf02165015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

RICH, JAMES, and MICHEL SPIRO. "Radiochemical Solar Neutrino Experiments." Annals of the New York Academy of Sciences 688, no. 1 (1993): 364–75. http://dx.doi.org/10.1111/j.1749-6632.1993.tb43910.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Vučina, J. L., D. A. Vuga, and N. S. Vukićević-Nikolić. "Radiochemical purity of99mTc radiopharmaceuticals." Journal of Radioanalytical and Nuclear Chemistry Letters 199, no. 2 (1995): 135–42. http://dx.doi.org/10.1007/bf02162476.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Bujdosó, E. "Radiochemistry and radiochemical separations." Journal of Radioanalytical and Nuclear Chemistry 230, no. 1-2 (1998): 327–35. http://dx.doi.org/10.1007/bf02387492.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Bujdosó, E. "Radiochemistry and radiochemical separations." Journal of Radioanalytical and Nuclear Chemistry Articles 100, no. 1 (1986): 219–30. http://dx.doi.org/10.1007/bf02036516.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Bujdosó, E. "Radiochemistry and radiochemical separations." Journal of Radioanalytical and Nuclear Chemistry Articles 182, no. 2 (1994): 489–95. http://dx.doi.org/10.1007/bf02037526.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Bujdosó, E. "Radiochemistry and radiochemical separations." Journal of Radioanalytical and Nuclear Chemistry Articles 102, no. 1 (1986): 269–81. http://dx.doi.org/10.1007/bf02037967.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Bujdosó, E. "Radiochemistry and radiochemical separations." Journal of Radioanalytical and Nuclear Chemistry Articles 196, no. 2 (1995): 393–404. http://dx.doi.org/10.1007/bf02038060.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Bujdosó, E. "Radiochemistry and radiochemical separations." Journal of Radioanalytical and Nuclear Chemistry 218, no. 2 (1997): 273–80. http://dx.doi.org/10.1007/bf02039350.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Bujdosó, E. "Radiochemistry and radiochemical separations." Journal of Radioanalytical and Nuclear Chemistry Articles 121, no. 1 (1988): 221–34. http://dx.doi.org/10.1007/bf02041463.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Bujdosó, E. "Radiochemistry and radiochemical separations." Journal of Radioanalytical and Nuclear Chemistry Articles 90, no. 2 (1985): 439–71. http://dx.doi.org/10.1007/bf02060800.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Bujdosó, E. "Radiochemistry and radiochemical separations." Journal of Radioanalytical and Nuclear Chemistry Articles 139, no. 2 (1990): 381–91. http://dx.doi.org/10.1007/bf02061825.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Bujdosó, E. "Radiochemistry and radiochemical separations." Journal of Radioanalytical and Nuclear Chemistry Articles 149, no. 2 (1991): 361–81. http://dx.doi.org/10.1007/bf02062066.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Chaerunisa, Hasna, N. Elly Rosilawati, and Muchtaridi Muchtaridi. "Radiochemical Purity Test of Fractionated Sestamibi Kit Labelled with Technetium-99m." Indonesian Journal of Pharmaceutical Science and Technology 9, no. 2 (2022): 106. http://dx.doi.org/10.24198/ijpst.v9i2.33332.

Full text

Abstract:

Coronary Heart Disease (CHD) is a heart disorder caused by blockage of blood vessels. CHD can bedetected by Myocardial Perfusion Imaging (MPI). MPI is performed by injecting a radiopharmaceuticalinto the patient's body. 99mTc-sestamibi is a radiopharmaceutical that is commonly used in MPI.Sestamibi is available in the form of a multidose vial, but the cost of the examination will be expensiveif it is only used for one patient. Cost effectiveness can be increased by fractionating the sestamibi kitbefore labelled by 99mTc. 99mTc-sestamibi needs to be tested for quality control before it is administeredto the patients. One of the tests is the radiochemical purity test. The aim of this study was to determinethe radiochemical purity of the fractionated sestamibi kit labelled by 50 mCi 99mTc. 2 vials of sestamibikit was fractionated by adding 5 mL of 0.9% NaCl solution to each vial and divided into 10 new vials.Radiochemical purity was measured using the thin layer chromatography (TLC) method. The resultsof this study indicated that all samples had radiochemical purity of 100% up to 6 hours after labellingKeywords: Radiopharmaceutical, 99mTc-sestamibi, fractionation, radiochemical purity

APA, Harvard, Vancouver, ISO, and other styles

40

Sanad, M. H., Fawzy A. Marzook, Ayman B. Farag, Sudip Kumar Mandal, Syed F. A. Rizvi, and Jeetendra Kumar Gupta. "Preparation, biological evaluation and radiolabeling of [^99mTc]-technetium tricarbonyl procainamide as a tracer for heart imaging in mice." Radiochimica Acta 110, no. 4 (2022): 267–77. http://dx.doi.org/10.1515/ract-2021-1079.

Full text

Abstract:

Abstract This study focuses on the synthesis and preliminary bio-evaluation of [99mTc]-technetium tricarbonyl procainamide ([99mTc]-technetium tricarbony PA) as a viable cardiac imaging agent. The compound, [99mTc]-technetium tricarbony PA, was synthesized by labelling procainamide with a [99mTc]-technetium tricarbonyl core, yielding a high radiochemical yield and radiochemical purity of 98%. Under optimal circumstances, high radiochemical yield and purity were obtained utilizing [99mTc]-technetium tricarbonyl core within 30 min of incubation at pH 9, 200 µg substrate concentration, and 100 °C reaction temperature. The heart showed a high absorption of 32.39 ± 0.88% of the injected dose/g organ (ID/g), confirming the suitability of [99mTc]-technetium tricarbonyl PA as a viable complex for heart imaging.

APA, Harvard, Vancouver, ISO, and other styles

41

Pascali, Giancarlo, Daniele Panetta, Mariarosaria De Simone, et al. "Preliminary Investigation of a Novel 18F Radiopharmaceutical for Imaging CB2 Receptors in a SOD Mouse Model." Australian Journal of Chemistry 74, no. 6 (2021): 443. http://dx.doi.org/10.1071/ch20247.

Full text

Abstract:

We successfully radiolabelled a novel prospective cannabinoid type 2 receptor ligand with 18F and tested its biodistribution in animal models by positron emission tomography (PET)/computed tomography (CT) imaging. The radiolabelling process was conducted on an alkyl mesylate fragment of the main naphthyridine core, using highly efficient microfluidic technology. No preliminary protection was needed, and the product was purified by semi-prep HPLC and SPE formulation, allowing the desired diastereomeric mixture to be obtained in 29% radiochemical yield and&gt;95% radiochemically pure. SOD1G93A mice were used as model of overexpression of CB2 receptors; PET imaging revealed a significant increase of the tracer distribution volume in the brain of symptomatic subjects compared with the asymptomatic ones.

APA, Harvard, Vancouver, ISO, and other styles

42

Matesic, Lidia, Ivan Greguric, and Giancarlo Pascali. "Microfluidic Radiosynthesis of the Muscarinic M2 Imaging Agent [18F]FP-TZTP." Australian Journal of Chemistry 71, no. 10 (2018): 811. http://dx.doi.org/10.1071/ch18266.

Full text

Abstract:

3-(4-(3-[18F]Fluoropropylthio)-1,2,5-thiadiazol-3-yl)-1-methyl-1,2,5,6-tetrahydropyridine ([18F]FP-TZTP) is a selective 18F-radiotracer for the muscarinic acetylcholine receptor subtype M2, which can be used to perform positron emission tomography (PET) scans on patients with neurological disorders such as Alzheimer’s disease. [18F]FP-TZTP was produced using continuous-flow microfluidics, a technique that uses reduced amounts of chemical reagents, shorter reaction times and in general, results in higher radiochemical yields compared to currently used techniques. The optimal 18F-radiolabelling conditions consisted of a total flow rate of 40 µL min−1 and 190°C, which produced [18F]FP-TZTP in 26 ± 10 % radiochemical yield with a molar activity of 182 ± 65 GBq µmol−1 and >99 % radiochemical purity.

APA, Harvard, Vancouver, ISO, and other styles

43

Padgett, H. C., D. G. Schmidt, A. Luxen, G. T. Bida, N. Satyamurthy, and J. R. Barrio. "Computer-controlled radiochemical synthesis: A chemistry process control unit for the automated production of radiochemicals." International Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes 40, no. 5 (1989): 433–45. http://dx.doi.org/10.1016/0883-2889(89)90213-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Padgett, H. C., D. G. Schmidt, A. Luxen, G. T. Bida, N. Satyamurthy, and J. R. Barrio. "Computer-controlled radiochemical synthesis: A chemistry process control unit for the automated production of radiochemicals." Journal of Labelled Compounds and Radiopharmaceuticals 26, no. 1-12 (1989): 469–71. http://dx.doi.org/10.1002/jlcr.25802601201.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Collier, Thomas Lee, Steven H. Liang, J. John Mann, Neil Vasdev, and J. S. Dileep Kumar. "Microfluidic radiosynthesis of [18F]FEMPT, a high affinity PET radiotracer for imaging serotonin receptors." Beilstein Journal of Organic Chemistry 13 (December 29, 2017): 2922–27. http://dx.doi.org/10.3762/bjoc.13.285.

Full text

Abstract:

Continuous-flow microfluidics has shown increased applications in radiochemistry over the last decade, particularly for both pre-clinical and clinical production of fluorine-18 labeled radiotracers. The main advantages of microfluidics are the reduction in reaction times and consumption of reagents that often result in increased radiochemical yields and rapid optimization of reaction parameters for 18F-labeling. In this paper, we report on the two-step microfluidic radiosynthesis of the high affinity partial agonist of the serotonin 1A receptor, [18F]FEMPT (pK i = 9. 79; K i = 0.16 nM) by microfluidic radiochemistry. [18F]FEMPT was obtained in ≈7% isolated radiochemical yield and in >98% radiochemical and chemical purity. The molar activity of the final product was determined to be >148 GBq/µmol (>4 Ci/µmol).

APA, Harvard, Vancouver, ISO, and other styles

46

Shapiro, Brahm, Lorraine M. Fig, Milton D. Gross, Frederick Khafagi, and K. E. Britton. "Radiochemical Diagnosis of Adrenal Disease." Critical Reviews in Clinical Laboratory Sciences 27, no. 3 (1989): 265–98. http://dx.doi.org/10.3109/10408368909105716.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Herrling, P., A. Zürn, P. Anders, J. Kotzerke, and G. Wunderlich. "Chromatographic determination of radiochemical purity." Nuklearmedizin 49, no. 02 (2010): 73–77. http://dx.doi.org/10.3413/nukmed-0279.

Full text

Abstract:

SummaryThin layer chromatography is well established for quality control of radiopharmaceuticals. A convenient and widely used stationary phase are ITLC SG strips. However, the Pall Corporation stopped manufacturing of the silica gel impregnated glass fibre strips (ITLC SG). Material, Methode: As a replacement we tested silicic acid impregnated glass fibre strips from Varian (ITLC SA) and sufficient mobile phases. Results: The chromatography with these strips takes two to three times longer than with ITLC SG, but it is in an acceptable range. Only three mobile phases are necessary to test most of the common in-house made radiopharmaceuticals. Conclusion: The proposed method is suitable for routinely measuring the radiochemical purity of radiophamaceuticals.

APA, Harvard, Vancouver, ISO, and other styles

48

Dmitriev, S. N., Yu Ts Oganessian, and M. G. Itkis. "Radiochemical Investigations at the FLNR." Journal of Nuclear and Radiochemical Sciences 3, no. 1 (2002): 125–27. http://dx.doi.org/10.14494/jnrs2000.3.125.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Tadevosyan, Yuliya A., Maksim A. Semenov, and Elena S. Kiseleva. "Metrological assurance in radiochemical production." Reference materials 13, no. 2 (2017): 49–57. http://dx.doi.org/10.20915/2077-1177-2017-13-2-49-57.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Bondarkov, M., A. Maksimenko, and V. Zheltonozhsky. "Non radiochemical technique for90Sr measurement." Radioprotection 37, no. C1 (2002): C1–927—C1–931. http://dx.doi.org/10.1051/radiopro/2002226.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!